- Home
- BRLT vs CTXR Comparison
BRLT vs CTXR Comparison
Compare BRLT & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRLT | CTXR |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 18.7M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | BRLT | CTXR |
|---|---|---|
| Price | $1.40 | $0.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $1.70 | ★ $6.00 |
| AVG Volume (30 Days) | 122.3K | ★ 749.6K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $437,483,000.00 | N/A |
| Revenue This Year | $6.72 | N/A |
| Revenue Next Year | $4.95 | $147.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $1.00 | $0.47 |
| 52 Week High | $3.10 | $2.19 |
Technical Indicators
Market Signals| Indicator | BRLT | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 68.58 | 61.42 |
| Support Level | $1.25 | $0.68 |
| Resistance Level | $1.61 | $0.74 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 85.38 | 72.82 |
Price Performance
Historical ComparisonAbout BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.